You are here: Industry Insights > vaccines

News List

Roche's multiple sclerosis drug Ocrevus lowered patients' vaccine responses: study fiercepharma
June 07, 2018
Roche’s multiple sclerosis newcomer Ocrevus was approved by the FDA last March bearing a warning about immunization.
Where is Pfizer putting its R&D hopes? Vaccines are front and center fiercevaccines
May 17, 2018
On Pfizer’s first-quarter earnings call, CEO Ian Read drew up a long list of R&D programs the company’s expecting to drive future growth.
Where is Pfizer putting its R&D hopes? Vaccines are front and center fiercepharma
May 08, 2018
On Pfizer’s first-quarter earnings call, CEO Ian Read drew up a long list of R&D programs the company’s expecting to drive future growth. But when Bernstein analyst Tim Anderson asked him to narrow it down, Read mentioned vaccines first.
GSK's Shingrix blows past sales projections, pushing 2018 estimates to $600M fiercepharma
May 02, 2018
GlaxoSmithKline's Shingrix carried high expectations, but it turns out that those ambitious projections weren't high enough.
WHO South-East Asia emphasizes on life-saving vaccines biospectrumasia
April 23, 2018
At present, seven Member countries’ routine immunization programmes have achieved more than 90% coverage with three doses of the basic diphtheria, tetanus and pertussis vaccine
Sanofi ups the ante in vaccines with new €350M plant fiercepharma
April 18, 2018
Sanofi CEO Olivier Brandicourt took a hard look at the French drugmaker's operations after he took the helm—and he put its vaccines business front and center in the company's growth plans.
Merck Helps Accelerate Global Access to Affordable Vaccines prnasia
April 13, 2018
Merck, a leading science and technology company today announced a partnership with Oxford University's Jenner Institute to develop more robust and scalable vaccine manufacturing processes.
CEPI grants Themis $37.5M for Lassa and MERS vaccines fiercepharma
March 08, 2018
CEPI signed its first company agreement, granting Themis an investment of up to $37.5 million to develop new vaccines against Lassa fever and MERS.
New initiative to accelerate development of universal influenza vaccines europeanpharmaceuticalreview
October 30, 2017
Universal Influenza Vaccine Initiative will address the underlying scientific barrier impeding the development of broadly protective, universal influenza vaccines…
News of Note—VBI Vaccines, BiondVax and more fiercepharma
September 06, 2017
VBI Vaccines won FDA approval for its phase 3 program of hep B shot Sci-B-Vac. Enrollment is expected to start this year in the U.S., Europe and Canada. The vaccine is already licensed in Israel and 14 other countries. Release

Previous page 1 2 3 4 5 6 7 8 9 10 11 12 13 Next page